Advantage Therapeutics Inc. Forms Klothea Bio, Inc. for Klotho Protein R&D in Age-Related Therapies

Advantage Therapeutics Inc., a prominent developer of therapies for age-related diseases, has announced the launch of its new subsidiary, Klothea Bio, Inc. This new entity will concentrate on the research and development of Klotho-based therapies aimed at preventing and treating various age-related conditions. The initiative is backed by seed funding, with Longevitytech.fund (LTF) as the lead investor. LTF is a venture capital fund managed by Petr Sramek, focusing on biotechnology startups that aim to extend healthy lifespans globally.

Klothea Bio will leverage Advantage Therapeutics' proprietary intellectual property portfolio that revolves around Klotho, a protein known for its substantial anti-aging properties. These properties include neuroprotection, antioxidative effects, and tumor suppression. With age, Klotho levels decline to potentially harmful levels. Klothea Bio's initial studies will focus on metabolic disease syndrome, with plans to expand research to other age-related diseases like cancer, Alzheimer’s disease, and obesity.

Jeffrey Madden, Chairman of Klothea Bio, expressed optimism about the potential of their mRNA therapy to increase Klotho levels to those found in young, healthy individuals. He believes this could offer long-lasting therapeutic effects, potentially delaying or preventing certain age-related diseases. Madden also emphasized the strategic importance of the investment from Longevitytech.fund, which he believes will advance Klothea Bio’s mission to harness the transformative potential of Klotho protein therapies for aging-related ailments. This collaboration is seen as a critical step towards developing safe and effective treatments, with upcoming clinical trials in the pipeline.

Petr Sramek, Managing Partner of Longevitytech.fund and a member of Klothea Bio’s board, shared his excitement about supporting the company’s mission. He highlighted Longevitytech.fund's commitment to finding solutions that address the hallmarks of aging. Sramek sees Klotho as a crucial protein in the molecular pathway that can enhance human health and longevity. By supporting Klothea Bio, Longevitytech.fund aims to promote pioneering science that could reduce the burden of age-related diseases.

Dr. Carmela Abraham, Chief Science Officer at Advantage Therapeutics, has studied Klotho for over two decades. She has developed several modalities to increase Klotho levels and is enthusiastic about transforming Klotho boosting into a therapy that could improve both healthspan and lifespan. Dr. Abraham expressed her delight in working with Petr Sramek and his team to advance this vision.

About Klothea Bio Inc.
Klothea Bio is dedicated to the research and development of therapies centered around Klotho, a protein with significant anti-aging properties. Klotho is expressed in various cells, particularly in the kidneys and brain, and acts as a circulating hormone with numerous health benefits, including neuroprotection, antioxidative effects, and tumor suppression. The decline in Klotho levels with age is linked to several age-related disorders, such as cognitive decline, chronic kidney disease, and cancer. Klothea Bio is pioneering an innovative approach using mRNA technology to boost the body’s Klotho production, potentially offering sustained therapeutic effects that could revolutionize anti-aging treatments.

About Advantage Therapeutics Inc.
Advantage Therapeutics, Inc. is at the forefront of developing next-generation therapies for Alzheimer’s disease and other age-related conditions. The company is dedicated to addressing the unmet medical needs of patients through cutting-edge science and innovative treatment approaches, aiming to significantly impact healthspan and longevity.

Advantage Therapeutics’ lead compound, AD04™, is a subcutaneous injectable therapy with planned Phase 2b clinical trials in Europe and the UK. These trials will evaluate its safety and efficacy in early Alzheimer’s disease patients. AD04™ is believed to act as an immunomodulator, stimulating and regulating the immune system to reduce Alzheimer’s disease pathology. Rather than targeting misfolded proteins like beta amyloid and tau, AD04™ aims to restore gene expression in lipid metabolism, improve phagocytosis, and reduce inflammation.

About Longevitytech.fund
Longevitytech.fund is a venture capital fund focusing on early-stage biotech startups and university spinoffs worldwide. By collaborating with top scientists in aging research, biotechnology, bioinformatics, agetech, and AI, Longevitytech.fund provides active support and commercialization assistance for its portfolio companies.